A Phase I/Ib, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MED13617, a Human Monoclonal Antibody Directed Against ANG2, as a Single-Agent or in Combination Therapy in Adult Subjects with Advanced Solid Tumors

This is a first time in human (FTIH), Phase I/Ib, multicenter, open-label, single-arm, dose-escalation and dose-expansion study of MED13617 to evaluate the safety, tolerability, antitumor activity, and pharmacology of MED13617 as a single-agent or in combination therapy in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists. Approximately 5-10 investigational sites in the United States of America (USA) will participate in the dose-escalation and dose-expansion arms of the study. Based on each sites' IRB regulatory approval, sites may enroll subjects into the Phase I dose-escalation and dose-expansion arms or the Phase Ib dose-escalation and dose-expansion arms, or both phases of the study.

Study Number: 

I 215812

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.